Cargando...
Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy
OBJECTIVE: Nearly 5% of patients with breast cancer carry germline BRCA mutations, which are more common in triple-negative breast cancer (TNBC). Previous clinical trials demonstrated the therapeutic efficacy of poly (ADP-ribose) polymerase inhibitors (PARPis) against BRCA-mutated metastatic breast...
Gardado en:
| Publicado en: | J Int Med Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8164563/ https://ncbi.nlm.nih.gov/pubmed/33541181 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0300060521991019 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|